Shots:

• Genmab to receive $750M as up front and is eligible to receive ~$3.15B as development- regulatory & commercial milestones for all programs along with royalties (22% - 26%) on sales for epcoritamab (ex- US & Japan). The collaboration includes development and commercialization of the three bispecific Ab therapeutic candidates
• The parties equally share pre-tax profits from the sale of products included milestones up to $1.15B related to clinical development and commercial success across the three existing bispecific Abs programs. In addition- if all four next-generation Abs emerges research collaboration are successful- Genmab is eligible to receive up to $2B as option exercising payment and milestones
• The companies will share commercialization of epcoritamab in the US & Japan- with AbbVie to lead global commercialization while Genmab will book net sales in the territories and receive royalties on remaining global sales. The companies will share responsibilities for global development & commercialization for DuoHexaBody-CD37- DuoBody-CD3x5T4 and any emerging product in the US & Japan while jointly retain the right to co-commercialize these products outside the US and Japan. Additionally- Genmab to conduct P-I studies for these programs for which AbbVie retains the right to opt-in to program development

Click here to read full press release/ article 

Ref: Genmab | Image: AbbVie